(281) 713-2962
800 Rockmead Drive, Suite 155
Kingwood, TX 77339
[email protected]
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Status: Recruiting
Location: aTyr Investigative Site
Conditions: aTyr Investigative Site
City/State:
Birmingham, Alabama
Los Angeles, California
Newport Beach, California
Valencia, California
Denver, Colorado
Gainesville, Florida
Tampa, Florida
Atlanta, Georgia
Chicago, Illinois
Kansas City, Kansas
Louisville, Kentucky
New Orleans, Louisiana
Baltimore, Maryland
Boston, Massachusetts
Ada, Michigan
Detroit, Michigan
Royal Oak, Michigan
Minneapolis, Minnesota
Rochester, Minnesota
Jackson, Mississippi
Saint Louis, Missouri
Albany, New York
Durham, North Carolina
Greenville, North Carolina
Cincinnati, Ohio
Cleveland, Ohio
Oklahoma City, Oklahoma
Portland, Oregon
Charleston, South Carolina
Dickson, Tennessee
Nashville, Tennessee
Dallas, Texas
Houston, Texas
Salt Lake City Utah
Falls Church, Virginia
Richmond, Virginia
Contact Information:
aTyr Pharma Clinical Research
877-215-5731
[email protected]
Brief Summary:
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.